Protocol Ledger

NCT05239039 · Phase III · COMPLETED

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Interventional Phase III clinical trial protocol NCT05239039 sponsored by Boehringer Ingelheim in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-15 Enrollment: 39 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05239039
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)39 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05239039
Protocol FieldVerified Registry Value
NCT IdentifierNCT05239039
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment39 participants (ACTUAL)
Registered Start Date2022-03-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05239039
Hospital Research SiteLocationSite Profile
The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaOpen Hospital Dossier ->
The First Hospital of China Medical UniversityShenyang, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI